/

STOK

Stoke Therapeutics, Inc.Open

22.69−1.46 −6.05%USD

NasdaqGS · as of Oct 13, 12:39 ET · 15m delay

Open

24.06

Prev close

24.15

Day range

22.6824.06

52-week range

20.3240.22

Volume

143.12K0.17×

Mkt cap

1.46B

P/E ttm

—

Fwd P/E

-6.43

EPS ttm

-3.38

Div yield

0.00%

Earnings

Aug 3, 2026

From 52w high

−43.59%

Price Chart

Yahoo Finance · delayed

STOKOct 13, 2026O 24.06H 24.06L 22.68C 22.69−1.46 (−6.05%)Vol 143.12K

SMA 5029.18
SMA 20031.36

1Y change −24.84% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

STOK Stoke Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −6.89%
1 month: −21.84%
3 months: −22.11%
6 months: −36.73%
Year to date: −28.51%
1 year: −25.21%

Valuation & ownership

Market cap: 1.46B
Enterprise value: 1.27B
P/E (ttm): —
Forward P/E: -6.43
PEG ratio: —
Price / book: 4.10
Price / sales (ttm): 53.07
EV / EBITDA: -5.72
EPS (ttm): -3.38
EPS (forward): -3.53
Beta (5y monthly): 1.26
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 64.53M
Float: 45.61M
Short % of float: 18.52%
Short ratio (days): 12.49
Held by insiders: 3.68%
Held by institutions: 125.34%
Avg volume (3m): 856.64K
50-day average: 29.31
200-day average: 31.41
52-week change: −25.21%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 27.6
vs 50-day SMA: −22.23%
vs 200-day SMA: −27.65%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.52%
Realised vol (20d, ann.): 56.0%
From 52-week high: −43.59%
From 52-week low: +11.66%

ANR

Analyst Consensus

13 analysts

Consensus

Strong buy

1.14 on a 1 (strong buy) – 5 (sell) scale

Mean target

46.46

+104.77% implied

Low 35.00Median 44.00High 60.00

Recommendation trend

Now14 / 0 / 0
1m ago14 / 0 / 0

DES

About Stoke Therapeutics, Inc.

Yahoo Finance profile

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 170
Headquarters: Bedford, MA, United States
Website: stoketherapeutics.com
Officers: Mr. Ian F. Smith A.C.A., C.P.A. CEO & Director

SEAS

Seasonality · STOK

2019–2026 · monthly returns

Strongest month May +15.74%Weakest month Sep −10.38%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-4.4	20.0	-10.6	0.5	-5.5	5.9	-11.8	8.1	-16.7	-12.7			−28.5%
2025	4.1	-31.6	-15.3	46.8	-2.3	19.0	13.2	53.8	18.9	27.8	2.9	2.7	+187.8%
2024	-8.0	59.9	74.4	-18.3	32.5	-7.6	10.8	-2.8	-15.5	0.6	-2.0	-8.9	+109.7%
2023	7.9	-10.7	-6.3	6.7	26.0	-5.1	-37.5	-15.4	-29.9	-3.3	-0.5	38.8	−43.0%
2022	-21.0	2.9	7.9	-31.4	-16.1	9.1	12.0	1.8	-14.7	15.7	-49.2	22.4	−61.5%
2021	-1.4	-1.9	-35.1	-16.8	22.8	-15.1	-14.9	-8.6	-2.8	-10.3	9.1	-3.7	−61.3%
2020	-1.3	-11.5	-7.5	-8.2	31.5	-13.8	5.7	16.6	14.0	14.6	35.7	18.9	+118.7%
2019							-15.5	51.9	-42.6	31.9	-13.5	15.6	−2.9%

INSD

Insider Activity · STOK

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

42.3K shares

Sells, 6 months

45.6K shares

Net shares

−3.4K

Net change in insider shares

−0.10%

Date	Insider	Transaction	Shares	Value
Aug 31, 2026	Ticho Baruch SOfficer	Sale at price 30.51 - 31.06 per share.	5.5K	$170.06K
Aug 17, 2026	Kaye Edward MDirector	Sale at price 32.01 - 32.47 per share.	12.6K	$402.53K
Aug 17, 2026	Ticho Baruch SOfficer	Sale at price 32.01 - 32.47 per share.	4.8K	$152.69K
Aug 17, 2026	Allan JonathanGeneral Counsel	Sale at price 32.01 - 32.47 per share.	2.9K	$91.64K
Aug 13, 2026	Kaye Edward MDirector	—	26.3K	—
Aug 13, 2026	Ticho Baruch SOfficer	—	10K	—
Aug 13, 2026	Allan JonathanGeneral Counsel	—	6K	—
Aug 2, 2026	Ticho Baruch SOfficer	Sale at price 28.95 - 29.45 per share.	7.2K	$208.38K
Jun 30, 2026	Ticho Baruch SOfficer	Sale at price 32.62 - 33.27 per share.	7.2K	$236.07K
Jun 15, 2026	Allan JonathanGeneral Counsel	Sale at price 29.95 per share.	1.5K	$43.64K
May 31, 2026	Ticho Baruch SOfficer	Sale at price 30.58 per share.	1.8K	$54.89K
Apr 30, 2026	Ticho Baruch SOfficer	Sale at price 32.79 per share.	2.2K	$73.55K
Mar 31, 2026	Ticho Baruch SOfficer	Sale at price 32.66 per share.	1.8K	$60.03K
Mar 19, 2026	Allan JonathanGeneral Counsel	Sale at price 33.64 - 34.41 per share.	9.3K	$313.04K
Mar 18, 2026	Ticho Baruch SOfficer	Sale at price 29.99 - 33.38 per share.	14.3K	$456.83K
Mar 18, 2026	Ticho Baruch SOfficer	Conversion of Exercise of derivative security at price 2.19 per share.	1.4K	$2.99K
Mar 17, 2026	Hoitt JasonOfficer	Sale at price 31.28 - 33.38 per share.	3.7K	$119.31K
Mar 17, 2026	Leggett ThomasChief Financial Officer	Sale at price 31.28 - 33.38 per share.	4.6K	$147.15K
Mar 17, 2026	Allan JonathanGeneral Counsel	Sale at price 31.28 - 33.38 per share.	8.9K	$285.90K
Mar 12, 2026	Levin Arthur A.Director	Sale at price 36.80 per share.	605	$22.26K

STOK

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

STOK

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Stoke Therapeutics, Inc.

Seasonality · STOK

Insider Activity · STOK

Congress Trades · STOK

Investors Holding STOK

Investors Holding STOK

Congress Trades · STOK

Insider Activity · STOK

Seasonality · STOK

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Stoke Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News